Also known as Bremelanotide · Vyleesi
Melanocortin-4 receptor agonist FDA-approved for HSDD in premenopausal women.
Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin agonist with preferential activity at MC4R. Approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist with preferential activity at the MC4R receptor. It is a metabolite of Melanotan II, refined away from pigmentation toward central sexual-response pathways.
Unlike vascular treatments for sexual dysfunction, PT-141 acts in the central nervous system on the circuits that govern desire and arousal. It is FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women.
MC4R-preferential melanocortin agonism in CNS sexual-response circuits.
Behind every vial of PT-141 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how PT-141, specifically, is brought into being.
On paper, PT-141 is C50H68N14O10 — about 1,025.2 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
PT-141 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries cyclization, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — PT-141 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of PT-141 proves itself: identity confirmed by mass spectrometry against its ~1,025.2 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of PT-141 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing PT-141 to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning PT-141, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
PT-141 (bremelanotide) is a melanocortin MC4R agonist FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
Those act on blood flow; PT-141 acts centrally, on the brain circuits that govern sexual desire and arousal.
PT-141 is a metabolite of Melanotan II, refined toward MC4R and sexual-response activity and away from pigmentation.
No — this page is a research and educational reference, not medical advice.
Synthetic cyclic analog of α-MSH; non-selective melanocortin receptor agonist.
ViewC-terminal decapeptide fragment of kisspeptin; potent GnRH secretagogue.
ViewA heterodimeric glycoprotein hormone — two different glycosylated subunits — that mimics the LH surge; the pregnancy hormone, also the subject of a debunked diet.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.